ACT Biotech Inc Company Overview and Financial Data

ACT Biotech Inc is a biotechnology company that has made significant strides in developing innovative treatments for various diseases.

Their company overview reveals a strong focus on research and development, with a team of experts working tirelessly to bring new therapies to market.

ACT Biotech Inc has a relatively small market capitalization, with a current value of approximately $50 million.

Their financial data shows a steady increase in revenue over the past few years, with a notable spike in 2020.

ACT Biotech Inc has a relatively modest annual revenue, which was $7 million in 2025.

The company's financial performance is a key indicator of its overall health and stability.

ACT Biotech Inc's annual revenue was $7 million in 2025, providing a clear picture of its financial standing at that time.

A unique perspective: Fubon Group

The NAICS code is a crucial piece of financial information that helps identify a company's industry and classification.

The NAICS code for ACT Biotech Inc is 325, 3254, and 32.

These codes are used to categorize businesses and provide a standardized way of classifying industries.

The NAICS code for ACT Biotech Inc specifically falls under the 3254 category, which is a more detailed classification within the larger 325 category.

The NAICS code is used by the US government to collect statistical data and monitor economic trends.

ACT Biotech Inc reported an annual revenue of $7 million in 2025.

The annual revenue of a company can have a significant impact on its financial health and stability.

ACT Biotech Inc's annual revenue of $7 million in 2025 is a relatively modest figure.

This revenue figure can be compared to other financial metrics to get a more comprehensive picture of the company's financial situation.

ACT Biotech Inc's annual revenue of $7 million in 2025 is a specific data point that can be used to inform business decisions and strategies.

For another approach, see: KB Financial Group

ACT Biotech has raised a total funding of $9.07M over 4 rounds, with its first funding round taking place on May 06, 2008.

The company has 2 institutional investors, NGN Capital and Sobera Capital, who have backed its growth.

ACT Biotech has received funding in three Series A rounds, with the first one occurring on Apr 27, 2010, for $1M.

The post-money valuation after the Apr 27, 2010, funding round was $6,837,355.

Here's a breakdown of ACT Biotech's funding rounds:

ACT Biotech Inc. has had its fair share of significant milestones, one of which is the acquisition of global oncology rights.

In 2008, ACT Biotech was formed through a license agreement with Bayer HealthCare LLC. As part of this agreement, ACT Biotech acquired a portfolio of clinical and early-stage oncology assets.

The company raised $12 million in the first tranche of a Series A financing led by NGN Capital, New York. This financing was part of a larger goal to raise a total of $20 million, which was expected to be completed in the second quarter of 2008.

Intriguing read: Clovis Oncology

ACT Biotech has also secured funding through multiple rounds, with a total of $9.07 million raised over 4 rounds. The first funding round was on May 6, 2008.

Here's a breakdown of ACT Biotech's funding rounds:

ACT Biotech Inc is a company that has been making waves in the biotech industry. They have developed a unique approach to cancer treatment.

ACT Biotech Inc's approach focuses on targeting cancer stem cells, which are thought to be responsible for cancer recurrence. This is a promising area of research.

The company's technology has shown promising results in preclinical trials. These trials have demonstrated the ability to selectively kill cancer stem cells while sparing healthy cells.

ACT Biotech Inc's technology has the potential to improve cancer treatment outcomes. This could lead to better patient survival rates and reduced side effects.

The company is working to advance their technology through further research and development. They are collaborating with other experts in the field to refine their approach.